NASDAQ
Maze Therapeutics, Inc. (MAZE) has a free cash flow growth of -41.21% as of Friday, May 29, 2026. This represents a 560.84% decrease compared to its 12-month average of -6.24%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.